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Study objectives: To examine the proportion of the recent decline in coronary heart disease (CHD) deaths
in Ireland attributable to (a) ‘‘evidence based’’ medical and surgical treatments, and (b) changes in major
cardiovascular risk factors.
Design setting: IMPACT, a previously validated model, was used to combine and analyse data on the use and
effectiveness of specific cardiology treatments and risk factor trends, stratified by age and sex. The main data
sources were published trials and meta-analyses, official statistics, clinical audits, and observational studies.
Results: Between 1985 and 2000, CHD mortality rates in Ireland fell by 47% in those aged 25–84. Some
43.6% of the observed decrease in mortality was attributed to treatment effects and 48.1% to favourable
population risk factor trends; specifically declining smoking prevalence (25.6%), mean cholesterol
concentrations (30.2%), and blood pressure levels (6.0%), but offset by increases in adverse population
trends related to obesity, diabetes, and inactivity (213.8%).
Conclusions: The results emphasise the importance of a comprehensive strategy that maximises population
coverage of effective treatments, and that actively promotes primary prevention, particularly tobacco
control and a cardioprotective diet.
C
oronary heart disease (CHD) remains a leading cause of
death and disability in Ireland, and mortality rates are
still among the highest in Europe.1 However, CHD
mortality rates have halved since the mid-1980s, with steeper
falls in younger age groups. This resulted in about 3765 fewer
deaths in 2000 compared with 1985 in Ireland.1 2 The
multinational MONICA study suggested that in countries
with falling CHD mortality rates, about one third of the fall
was attributable to improved case fatality (mostly treatment
related) and two thirds to a reduction in event incidence
(mostly attributable to risk factor reductions).3 4 It would be
of benefit to determine the components that have resulted in
the biggest decreases in mortality, to guide policy in the
prevention of CHD, focus health promotion strategies, and
target resources towards the most effective interventions in
the populations with the greatest need.
Since 1996, Capewell and colleagues have progressively
developed and refined a CHD mortality model called
IMPACT.5–7 This model has been used to explore trends in
CHD mortality in contrasting countries, and to comprehensively
assess the potential contribution of cardiology treatments and
risk factor changes. The model was validated against the actual
CHD mortality falls seen in Scotland, England, New Zealand,
and Finland5–8 before being used to assess substantial mortality
increases seen in China.9 Results using the IMPACT model were
generally consistent with other studies using diverse methodol-
ogies in different countries including the USA, New Zealand,
Finland, and the Netherlands.10–13
This study aimed to use the IMPACT CHD model to examine
the CHD mortality fall in Ireland between 1985 and 2000, and to
determine how much of this fall could be attributed to
‘‘evidence based’’ medical and surgical treatments, and how
much to changes in major cardiovascular risk factors.
METHODS
The IMPACT model
The cell based mortality model in Microsoft Excel has been
described in detail elsewhere.6 In brief, the number of CHD
deaths prevented or postponed by each specific cardiac
intervention and by each risk factor change was calculated
for Ireland for the base year 1985, and again for the year
2000.
We identified and incorporated data for men and women
aged 25 to 84 years in the Irish population of 3.8 million,
stratified by age and sex, detailing:
(a) CHD patient numbers, (ICD 9 codes 410–414) cate-
gorised by disease subgroup
(b) Use of specific medical and surgical treatments,
(c) Population trends in major cardiovascular risk factors
(smoking, total cholesterol, hypertension, obesity, dia-
betes, and physical inactivity),
(d) Effectiveness of specific cardiology treatments
(e) Effectiveness of specific risk factor reductions.
All public and private patients were included. Those aged
85 years or over were excluded from the model, because of
uncertainties regarding death certification accuracy.
Identification and assessment of relevant data
(tables 1, 2)
Information was obtained from routine health statistics,
mainly the Public Health Information System (PHIS),14
available from the Department of Health and Children,
Ireland; the Hospital Inpatient Enquiry (HIPE) system
available from the Economic and Social Research
Institute15; and other surveys.16 17 However, HIPE data do
not differentiate between first and recurrent events.
Prescription data were obtained from the General Medical
Services (GMS) payments board (http://www.gmspb.ie) and
risk factor data from two population studies, the Kilkenny
health project and the Cork and Kerry diabetes and heart
disease study.18 19 Data on the effectiveness of therapeutic
interventions and the mortality reduction from specific
population cardiovascular risk factor changes came from
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published randomised controlled trials, meta-analyses, and
cohort studies.20–22 Further details on the identification and
assessment of the relevant data can be found in appendices I-
III on the IMPACT web site.23
The fall in coronary heart disease deaths
The number of CHD deaths expected in 2000 if the mortality
rates in 1985 had persisted was calculated by indirect age
standardisation, using 1985 as the base year. The CHD deaths
actually seen in 2000 were then subtracted to give the
decrease in CHD deaths in 2000 compared with 1985 (3763
fewer deaths).
The model aimed to include all known medical and
surgical treatments in 1985 and 2000. These interventions
are listed in table 1, and included all the interventions
considered in earlier versions of the IMPACT model, plus
primary angioplasty including stenting for myocardial infarc-
tion, statins for primary prevention, platelet IIB/IIIA inhibi-
tors and clopidogrel for unstable angina, plus spironolactone
and b blockers for heart failure (table 1).
The mortality reduction for each treatment was calculated
using the relative mortality reduction reported in published
meta-analyses and trials applied to the age specific case-
fatality rate seen in large unselected patient cohorts.6
Polypharmacy issues
The potential effect of multiple treatments in an individual
patient was examined using the Mant and Hicks cumulative
relative benefit approach24:
Relative benefit = 1 2 [(12treatment A)6(12treatment
B) 6… etc
Potential overlaps between patient groups
Patient groups are seldom mutually exclusive. For example,
about half the patients having CABG surgery have had a
previous myocardial infarction, and about one fifth of
myocardial infarction survivors develop clinical heart failure
within 12 months. To avoid double counting, potential overlaps
between different groups of patients were identified and
adjustments were made using previously established methods.23
Treatment compliance
Compliance or concordance, the proportion of treated
patients actually taking therapeutically effective levels of
medication, was based on recent studies where available. The
IMPACT model default assumptions for compliance were
100% in hospital patients, 70% in symptomatic community
patients, and 50% in asymptomatic community patients.25
Deaths prevented or postponed
A number of effective therapies were already in limited use in
1985. These included CABG surgery, cardiopulmonary resus-
citation, b blockers for acute myocardial infarction (AMI),
diuretics for acute left ventricular heart failure, and therapy
for moderate and severe hypertension (then defined as a
diastolic blood pressure .105 mm Hg). Patient data for most
of these interventions, such as CABG surgery, and eligible
hypertensives, were obtained from the data sources detailed
above.
Risk factor trends and mortality benefits
Data on risk factors were obtained for the years 1985 and
2000 only.
(a) Regression coefficients
For risk factor changes, the model uses multiple regression
(b) coefficients obtained from meta-analyses, large cohort
studies, and MONICA analyses. Each b coefficient quantifies
the independent relation between population change in a
specific CHD risk factor, (such as smoking, cholesterol, or
blood pressure) and the consequent change in population
mortality rate from CHD using multiple regression analysis.
These coefficients were recently reviewed and updated.6 20–22
The subsequent reduction in deaths produced by the fall in
each major risk factor was then estimated as the product of
three variables: the number of CHD deaths seen in the base
year (1985), the relative reduction in that risk factor, and the
b coefficient.
(b) Population attributable risk fraction
Given the absence of suitable b coefficients for obesity,
diabetes, and physical activity, a separate, previously vali-
dated method was used. This was based on population
attributable risk fraction (PARF), calculated using the
conventional formula.6 23
The number of CHD deaths attributable to each specific
risk factor was calculated for 1985 and for 2000. The
difference between the two values then represented the
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deaths prevented or postponed because of the change in the
risk factor in the population.
Model validation: comparison with observed
mortality falls
The model estimate for the total deaths prevented or
postponed by all treatments plus all risk factor changes was
then summed and compared with the observed falls in
mortality for men and women in each specific age-sex group.
On an a priori basis, any shortfall in the overall model
estimate was then formally attributed to other, unmeasured
and unidentified risk factors. In other industrialised coun-
tries, this has ranged from 3% to 9%.5 8
Sensitivity analyses
Because of the uncertainties surrounding many of the values,
a multiway sensitivity analysis was performed using the
analysis of extremes method.26 (Illustrative examples of
Table 1 Deaths prevented or postponed by medical and surgical treatments in Ireland in 2000
Treatments
Number of
eligible patients*
% Eligible patients
treated Absolute risk reduction Best estimate (number) Best estimate (%)
Acute myocardial infarction (AMI) 3970 166` 4.4`
Community resuscitation 49 0.110 12 0.3
Hospital resuscitation 99 0.213 32 0.9
Thrombolysis 39`` 0.038 60 1.6
Aspirin 61`` 0.031 79 2.1
Primary angioplasty 4`` 0.056 8 0.2
b blockers 33 0.008 11 0.3
ACE inhibitors 19`` 0.001 11 0.3
Total secondary prevention 6781 18.01
Secondary prevention after infarction 37245 449 11.9
Aspirin 64`` 0.010 127 3.4
b blockers 33 0.012 92 2.4
ACE inhibitors 21`` 0.012 53 1.4
Statins 37`` 0.015 83 2.2
Warfarin 4 0.008 9 0.2
Rehabilitation 51 0.014 87 2.3
Secondary prevention after revascularisation 24438 0.028 229** 6.1**
Chronic angina 317 8.4
CABG surgery 18990 100 0.009 144 3.8
Angioplasty 11023 100`` 0.005 45 1.2
Community angina (aspirin+statin) 78873 75`` 0.002 128 3.4
Unstable angina 2432 33 0.9
Aspirin and heparin 59`` 0.012 17 0.5
Aspirin alone 30`` 0.013 8 0.2
Platelet IIB/IIIA inhibitors 48`` 0.007 8
Heart failure – 340 9.1
Hospital 1715 28`` – 150
Community 12940 56`` 190 5.1
Hypertension treatment 705648 37 0.001 59 1.6
Statins for primary prevention 915169 6`` 0.001 46 1.2
Total treatment effects in 2000 1639/3763 43.6
*Based on Hospital-In-Patient Enquiry, Central Statistics Office, and General Medical Payments Databases for the year 2000 only.23 Treatment uptakes are
weighted to sex and age groups by the year of death, and therefore not consistent with values in appendix III, and appendix III identifies the sources of treatment
uptakes in Ireland for the year 2000 only. `This value does not include the additional 47 AMI deaths attributable to treatment effect of 1985. 1This value equates to
 and ** together and does not include two additional deaths attributable to treatment effect of 1985. 3763 is total observed fewer CHD deaths in 2000, and
1639 sums up all the individual bold font values. ``These treatments were not generally available in 1985.
Table 2 Deaths prevented or postponed as a result of population risk factor changes in
Ireland
Risk factors
Relative changes in
risk factor*
b regression
coefficients Deaths prevented or postponed
(%) (%) (number) (%)
Positive trends
Smoking 214.2 0.51 964 25.6
Cholesterol 24.6` 2.46 1135 30.2
Population BP 27.21 1.67 228 6.1
Subtotals +2327 +61.9
Adverse trends
Relative risk
Physical inactivity +4.8 0.50 2154 24.1
Obesity +195.1** 1.57 2131 23.5
Diabetes +48.0 4.24 2232 26.2
Subtotals 2517 213.8
Total risk factor effects in 2000 1810/3763`` +48.1
*Ratio of the absolute difference between 1985 and 2000 to the baseline year (1985), and then weighted to age
and sex specific populations. Smoking prevalence: 1985 (33.6%) and 2000 (28.8%). `Total mean cholesterol
levels: 1985 (6.02 mmol/l) and 2000 (5.73 mmol/l). 1Mean diastolic blood pressure levels: 1985 (81 mm Hg)
and 2000 (75 mm Hg). No Irish data available, so based on the UK prevalence data. **Obesity prevalence:
1985 (8%) and 2000 (24%). Diabetes prevalence: 1985 (1.7%) and 2000 (2.5%). ``3763 is total observed
CHD deaths in 2000, and 1810 is the sum of +2327 and 2517 deaths.
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specific analyses and calculations are shown in the appen-
dices of the recent England and Wales model publication,6
and on the IMPACT web site23). This method does not entail
any probabilistic interpretation as in confidence interval
estimation.
RESULTS
Between 1985 and 2000, CHD mortality rates in Ireland fell
by 47% in men and in women aged 25–84. This resulted in
3763 fewer ‘‘observed’’ deaths in 2000 compared with the
expected number given the rates in 1985 (8681 expected
minus 4918 observed). Overall, the IMPACT model predicted
3449 fewer deaths, about 92% of the observed CHD mortality
fall (93% in men and 88% in women). The remaining 8% of
the mortality fall was attributed to other, unmeasured
factors.
Medical and surgical treatments
Medical and surgical treatments together prevented or
postponed about 1640 deaths (minimum estimate, 790;
maximum estimate, 3150; table 1). This represented 43.6%
of the total mortality decrease, after allowance for treatments
applied in 1985 (table 1). Substantial contributions came
from specific treatments for secondary prevention, heart
failure and angina.
About 166 deaths were prevented or postponed by
treatments for AMI in 2000 when an additional 47 AMI
deaths were accounted for because of the treatment effect of
1985; the biggest contributions came from cardiopulmonary
resuscitation (CPR), aspirin, and thrombolysis (table 1).
CABG surgery and angioplasty were estimated to explain
about 5% of the total mortality fall (table 1).
Adjustment for polypharmacy in individual patients
Applying the Mant and Hicks equation to the uptake of
multiple medications in individual patients would have
reduced the total deaths prevented or postponed by about
157 (14 in AMI, 56 in heart failure patients, and 87 in
secondary prevention).24
Major cardiovascular risk factors
Changes in the major cardiovascular risk factors together
produced a best estimate of 1810 fewer deaths (minimum
estimate, 1505; maximum, 2425; table 2). This therefore
accounted for 48.1% of the total mortality decrease between
1985 and 2000. The biggest contribution came from the
decreases in serum total cholesterol levels, and reductions in
smoking and blood pressure levels (table 2). Adverse trends
were seen for physical activity, obesity, and diabetes; they
together caused about 517 additional CHD deaths (table 2).
The prevalence of obesity increased by 195% and diabetes
prevalence increased by 48%. Indirect evidence suggested a
5% decrease in physical activity (table 2).
Sensitivity analyses, validation, and model fit
Figure 1 shows the results of the sensitivity analysis.
Proportional contributions of specific treatments and risk
factor changes to the CHD mortality reduction in Ireland are
presented as best estimate, plus minimum and maximum
estimates. The proportionate contribution of specific treat-
ments and risk factor changes to the overall decrease in CHD
mortality in Ireland between 1985 and 2000 remained
comparatively consistent. For instance, considering the initial
treatments of AMI, the best estimates were 4.4%, the
minimum contribution was 2.5%, and the maximum 9.8%.
Similarly, for risk factors, the best estimate for smoking for
instance, was 25.6%, the minimum was 17.7%, and the
maximum estimate was 38.3% (table 2).
Figure 2 shows the validation of the IMPACT model. The
model estimates suggest a good fit with the observed CHD
deaths across all age groups in both sexes.
DISCUSSION
CHD mortality rates in Ireland halved between 1985 and
2000, with 3673 fewer observed CHD deaths in 2000. About
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What this paper adds
About 44% of the decline in coronary heart disease mortality
in Ireland can be attributed to medical treatments, particu-
larly secondary preventative therapies and treatment of heart
failure. Around 48% of the fall is attributable to changes in
risk factors including substantial reductions in smoking and
cholesterol, but offset by increases in obesity, diabetes, and
physical inactivity.
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44% of this decrease was attributable to the combined effects
of modern cardiology treatments and 48% to reduction in
major risk factors, particularly smoking and cholesterol
levels. Changes in the three classic cardiovascular risk factors
(smoking, cholesterol, and blood pressure) contributed 61.9%
of the total CHD mortality decrease, which is also consistent
with studies in other developed countries6–8; where at least
80% of major CHD events in men can be attributed to these
factors.27 The multinational MONICA study likewise sug-
gested that about one third of the fall was attributable to
improved case fatality (mostly treatment related) and two
thirds to a reduction in event incidence (mostly attributable
to risk factor reductions).3 4 This contribution is crucial, and
current health promotion activities and public health policies
are targeted at reducing these risk factors in the Irish
population.
Risk factors
A significant contribution of the reduction in mortality
attributable to risk factors reflected a moderate decrease in
smoking prevalence, from 34% to 29% (a 5% absolute risk
reduction). However, almost 30% of the mortality decrease
came from a comparatively small reduction (4.6%) in
population total cholesterol level. This is consistent with
progressively healthier eating patterns among the general
Irish population over the past decade. Furthermore, small
cholesterol changes have big effects as recent meta-analysis
have shown.28 29 A recent Chinese study suggested that a
1 mmol/l rise in total cholesterol level was responsible for a
37% increase in CHD mortality,9 which has been replicated in
the Asia Pacific cohort studies collaboration meta-analyses.29
This emphasises the consistently large b coefficient quanti-
fied by Law and colleagues, (5.4 to 1.9 according to age,22
more recently 5.6 to 3.1 by age28), and highlights the potential
gains that would come from more substantial cholesterol
reductions in Ireland.
The smaller smoking contribution in Ireland may princi-
pally reflect the comparatively slow decline in Irish smoking
prevalence between 1985–2000, averaging 14%, (half that
seen in the UK and New Zealand over the same period).6 7
However, there is evidence of a steeper decline in smoking
prevalence after the successful implementation of a ban on
smoking in the workplace in Ireland in 2004.30
The adverse trends in obesity, diabetes, and physical
inactivity together contributed over 500 additional deaths in
2000. These cancelled out over half the benefit from 15 years
of cholesterol improvement. Furthermore, continuing dete-
riorations are expected, given the rising prevalence of
childhood and adult obesity suggested by recent health and
lifestyle surveys in Ireland, as elsewhere.31 In the Asia Pacific
cohort studies collaboration a 2 kg/m2 reduction in popula-
tion BMI decreased CHD risk by 11%.32
We used comparatively conservative regression b coeffi-
cients for smoking (0.51), cholesterol (2.46), and blood
pressure (1.67). All the b coefficients and relative risk values
used in the model were independent, being obtained from
multiple regression analyses. The interactions between the
major risk factors should therefore have been accounted for.
However, there may still be some overestimation as only a
limited range of risk factors were used in the study. The
MONICA study, for example, included smoking (yes or no),
systolic blood pressure, total cholesterol, and body mass
index.3
There was comparatively little space left in the model, for
potential mortality benefits from other, unquantified factors,
barely 8%. These other factors include deprivation, dietary
consumption of fish oils, antioxidants, and alcohol, and life
course factors. However, these and other novel risk factors
such as homocysteine, apolipoprotein B, and C reactive
protein are likely to be highly correlated with the major risk
factors already included, and their independent contribution
to future decline in CHD mortality may be modest.27 Some or
all may thus contribute to the 8% of the mortality fall not
explained by the model.
Interventions
Revascularisation by CABG surgery or angioplasty accounted
for only 5% of the total mortality decrease, much as in Britain
and the USA.6 10 This is a disappointingly small contribution
given the large financial resources allocated to these
interventions.33
The most substantial contributions in mortality decline
attributable to treatments came from secondary prevention
and heart failure treatments. However, although heart failure
treatments resulted in over 300 (9%) of deaths prevented or
postponed, this would gain few additional life years because
of the comparatively short life expectancy in these patients.
Similarly, thrombolysis accounted for only about 1.6% of
the deaths prevented or postponed. By contrast, aspirin
therapy for patients with angina in the community (2.2%)
prevented more than twice as many deaths as did treatment
for unstable angina patients in hospitals (0.9%), principally
reflecting the greater numbers involved (table 1).
Treatment uptake levels (the proportion of eligible patients
actually receiving appropriate therapies) were variable and
sometimes poor. Earlier work suggested that if even 80% of
eligible patients had received appropriate therapy, about
21 000 additional deaths might have been prevented or
postponed each year in England and Wales,34 equivalent to
almost 2000 fewer deaths in Ireland.
In a previous study in 2002, we found that the uptake of
statin therapy in those with established heart disease or
diabetes was low at 44%.35 Encouragingly however, in a
recently published report from the Irish Heartwatch pro-
gramme, enrolling 10 500 patients with established CHD
onto a primary care database, almost 74% were on some lipid
lowering therapy at their first visit and 84% by their fourth
visit.36
Limitations of the study
This study focused on the number of deaths rather than
events incidence or improvements in case fatality.5 6 There are
obvious limitations with this type of modelling study. It is
very dependent on the quality and extent of data available on
CHD risk factor trends and treatment uptakes. If the data are
sparse or the quality poor then explicit assumptions and
robust sensitivity analyses become essential when checking
the validity of the model.
The model included only those aged 25 to 84 years old,
because of very limited data in older groups. We considered
only deaths from CHD and ignored ‘‘competing causes’’ such
What is already known
Two thirds of deaths due to cardiovascular disease can be
attributed to three main risk factors; smoking, blood pressure,
and cholesterol levels.
Policy implications
These results have major public health implications, particu-
larly in relation to supporting the recent workplace smoking
ban introduced in Ireland in March 2004.
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as cancer. However, we would expect that reductions in
smoking would also decrease deaths from lung cancer and
several other cancers. The IMPACT model assumes that
estimates of efficacy from randomized controlled trials can
usually be generalised to effectiveness in clinical practice.6 37
Although this seems reasonable, further development work is
clearly needed.38 Risk factors and treatments were also
considered to act independently in the model, but there is a
paucity of literature on this issue. Finally, although lag times
were not explicitly considered, they may be comparatively
unimportant over 1.5 decades. Substantial mortality reduc-
tion occurs within one to four years of quitting smoking or
reducing cholesterol levels.20 22
Explicit assumptions can then be tested by sensitivity
analyses.26 Modelling studies provide a basis for assessing
potential improvements in uptake of effective treatments,
health promotion, and public health strategies.
In conclusion, about 48% of the recent CHD mortality
decrease in Ireland was attributed to reductions in major risk
factors, and 44% to medical and surgical therapies.
Comprehensive CHD strategies should therefore maximise
the population coverage of effective treatments and actively
promote primary prevention.
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